These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 12429650

  • 1. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
    McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M.
    Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
    [Abstract] [Full Text] [Related]

  • 2. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ.
    J Natl Cancer Inst; 2003 Mar 19; 95(6):458-70. PubMed ID: 12644539
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, Price JE.
    Clin Cancer Res; 2005 Jan 01; 11(1):306-14. PubMed ID: 15671560
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ.
    Clin Cancer Res; 2003 Dec 15; 9(17):6534-44. PubMed ID: 14695158
    [Abstract] [Full Text] [Related]

  • 5. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T.
    Cancer; 2005 May 01; 103(9):1800-9. PubMed ID: 15786421
    [Abstract] [Full Text] [Related]

  • 6. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R.
    J Cell Physiol; 2006 Jul 01; 208(1):220-8. PubMed ID: 16575905
    [Abstract] [Full Text] [Related]

  • 7. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH, Gorlick R.
    Cancer; 2008 May 15; 112(10):2119-29. PubMed ID: 18338812
    [Abstract] [Full Text] [Related]

  • 8. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ.
    J Natl Cancer Inst; 2004 Jan 07; 96(1):46-55. PubMed ID: 14709738
    [Abstract] [Full Text] [Related]

  • 9. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M.
    J Invest Dermatol; 2004 Feb 07; 122(2):400-5. PubMed ID: 15009722
    [Abstract] [Full Text] [Related]

  • 10. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA.
    Cancer Res; 2002 Jul 01; 62(13):3729-35. PubMed ID: 12097282
    [Abstract] [Full Text] [Related]

  • 11. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ.
    J Natl Cancer Inst; 2006 Jun 07; 98(11):783-93. PubMed ID: 16757703
    [Abstract] [Full Text] [Related]

  • 12. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma.
    Apte SM, Fan D, Killion JJ, Fidler IJ.
    Clin Cancer Res; 2004 Feb 01; 10(3):897-908. PubMed ID: 14871965
    [Abstract] [Full Text] [Related]

  • 13. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS, Woo CW, Mackall CL, Thiele CJ.
    J Natl Cancer Inst; 2002 Nov 20; 94(22):1673-9. PubMed ID: 12441322
    [Abstract] [Full Text] [Related]

  • 14. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
    Yoshitani K, Honoki K, Morishita T, Kido A, Miyauchi Y, Mii Y, Takakura Y.
    In Vivo; 2003 Nov 20; 17(3):255-8. PubMed ID: 12929576
    [Abstract] [Full Text] [Related]

  • 15. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB.
    J Pharmacol Exp Ther; 2000 Oct 20; 295(1):139-45. PubMed ID: 10991971
    [Abstract] [Full Text] [Related]

  • 16. Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression.
    Sanz-González SM, Castro C, Pérez P, Andrés V.
    Biochem Biophys Res Commun; 2004 May 14; 317(4):972-9. PubMed ID: 15094364
    [Abstract] [Full Text] [Related]

  • 17. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW.
    Mol Cancer Ther; 2004 May 14; 3(5):527-35. PubMed ID: 15141010
    [Abstract] [Full Text] [Related]

  • 18. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW, Honsawek S, Litz J, Buchdunger E.
    Clin Cancer Res; 2000 Aug 14; 6(8):3319-26. PubMed ID: 10955819
    [Abstract] [Full Text] [Related]

  • 19. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
    Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S.
    J Clin Endocrinol Metab; 2003 Apr 14; 88(4):1889-96. PubMed ID: 12679488
    [Abstract] [Full Text] [Related]

  • 20. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.
    Mol Cancer Ther; 2003 May 14; 2(5):471-8. PubMed ID: 12748309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.